ArticleCancer medicine2026
Association of Combined MET/HGF Expression With the Colorectal Cancer Immune Microenvironment: An Integrated Immunohistochemical and Multi-Database Analysis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo validate c-MET protein expression in colorectal cancer (CRC) and assess whether joint MET and hepatocyte growth factor (HGF) transcript expression provides descriptive information on tumor microenvironment features beyond MET alone.
methodsc-MET protein expression was evaluated by immunohistochemistry in 51 paired CRC and adjacent tissues. The Cancer Genome Atlas (TCGA) and TNMplot datasets assessed MET mRNA expression and clinicopathological associations; Kaplan-Meier Plotter evaluated unadjusted survival; and TIMER (Tumor Immune Estimation Resource) examined purity-adjusted immune correlations. In TCGA colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ) cohorts, samples were divided using cohort-specific median MET and HGF expression. ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) and CIBERSORT (Cell-type Identification by Estimating Relative Subsets of RNA Transcripts) compared inferred tumor purity, immune/stromal scores, and immune-cell composition. These computational estimates were not experimentally validated in this study.
resultsMET mRNA was elevated in CRC datasets, and c-MET protein H-scores were higher in CRC than in paired adjacent tissues. MET expression was not associated with the tested clinicopathological variables. High MET expression was associated with shorter overall and relapse-free survival in unadjusted analyzes. In both cohorts, the MET-high/HGF-low group generally showed higher estimated tumor purity and lower immune and stromal scores, whereas the MET-low/HGF-high group showed the converse pattern. Individual immune-cell subset differences were cohort dependent.
conclusionMET mRNA and c-MET protein are elevated in CRC. Joint MET/HGF expression may complement MET-only analysis by retaining discordant patterns associated with inferred tumor-cell and immune/stromal composition. These retrospective, algorithm-derived findings do not establish independent prognostic value, HGF/c-MET pathway activation or causality, or a basis for clinical patient stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.